×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Sirtuin Modulators for Parkinson's Disease
therapeutic
2,649 words
KG: Sirtuin Modulators for Parkinson's Disease
2026-03-29
kind:therapeutic
section:therapeutics
state:published
parkinson
sirtuin
nad+
mitochondrial
alpha-synuclein
Contents
Sirtuin Modulators for Parkinson's Disease
💊
Therapeutic Info
Name
Sirtuin Modulators for Parkinson's Disease
Summary
Therapeutic targeting of sirtuin pathways (SIRT1, SIRT2, SIRT3) in Parkinson's disease - mitophagy, alpha-synuclein acetylation, mitochondrial function, and clinical development
Knowledge Graph
Related Hypotheses (30)
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.48
Microbial Inflammasome Priming Prevention
Score: 0.58
Senescence-Activated NAD+ Depletion Rescue
Score: 0.60
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Smartphone-Detected Motor Variability Correction
Score: 0.56
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.38
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc
Score: 0.60
Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromat
Score: 0.52
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci
Score: 0.45
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.45
Ancestry-Adapted Mitochondrial Rescue Therapy
Score: 0.45
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.62
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove
Score: 0.59
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Membrane Cholesterol Gradient Modulators
Score: 0.52
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.51
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50
Proteostasis Enhancement via APOE Chaperone Targeting
Score: 0.50
Stress Granule Phase Separation Modulators
Score: 0.49
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.40
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.36
Show 25 more
Related Analyses (25)
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 20 more
Related Experiments (30)
Sirtuin Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Show 25 more